Latest filing published 26 Nov 2024 for TPG Inc..
Not enough history yet: 0 closed purchases, at least 2 are needed.
David Bonderman appears in 13 filings between June 3, 2016 and November 26, 2024, as a Director of TPG Inc. (7) and Kite Pharma, Inc. (6). Market trades are rare but large: 3 sales worth EUR 60.2 million, including EUR 58,277,357 on February 29, 2024, the day of two other sales, EUR 1,302,314 and EUR 651,138, all at TPG Inc. Median sale: EUR 1,302,314.
Two purchases, both on May 9, 2017 at Kite Pharma, Inc., are worth EUR 2,920,384 and EUR 245,822, EUR 3.2 million in all; they make up 40% of market trades. The rest includes 2 grants, 1 option exercise and 5 other filings.
The record is discontinuous: 1 filing in 2016, 5 in 2017, 2 in 2023 and 5 in 2024. None falls in the last twelve months. Median publication delay: 2 days.
At TPG, 3 of David Bonderman's own market trades fall within 30 days of trades by each of Anilu Vazquez-Ubarri, Bradford Berenson, David Trujillo, Deborah M. Messemer and Ganendran Sarvananthan, all in the same direction.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations